1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,833 | 0,837 | 10:26 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 50,36 | +1,06 % | Novonesis (Novozymes A/S): Resolutions from the Annual General Meeting 2026 | Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit... ► Artikel lesen | |
| GENMAB | 226,10 | +0,18 % | Wolfe Research initiates Genmab stock with outperform rating | ||
| ARBUTUS BIOPHARMA | 3,850 | -0,41 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery... ► Artikel lesen | |
| VERICEL | 25,800 | -3,73 % | Vericel-Aktie erreicht Jahrestief bei 29,21 USD | ||
| MUSTGROW BIOLOGICS | 0,345 | 0,00 % | JETZT über 50 % KURSPOTENZIAL!? BioNTech, TUI und Bayer-Partner MustGrow | Lust auf ein Investment in einen Geheimtipp mit riesigem Marktpotenzial? Dann ist die Aktie von MustGrow interessant. Das Unternehmen wird mit unter 40 Mio. CAD bewertet. Die biologischen und regenerativen... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,430 | +1,25 % | Moleculin Biotech, Inc.: Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout | First Interim Unblinding of Pivotal AML Trial Now Imminent - Potentially the Most Important Data Moment in Company HistoryEarly Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 27,700 | +3,05 % | Sensei Harbor Corp. - S-1, General form for registration of securities | ||
| BIOXCEL THERAPEUTICS | 1,180 | -0,34 % | BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI Approval in Outpatient Setting | sNDA submitted seeking approval of IGALMI in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports... ► Artikel lesen | |
| REGENXBIO | 7,150 | -0,69 % | REGENXBIO Inc.: Regenxbio Reports New Positive Interim Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne
Pivotal dose participants exceeded external controls across... ► Artikel lesen | |
| AKEBIA | 1,178 | -1,17 % | Akebia Therapeutics, Inc.: Akebia Announces Establishment of Rare Kidney Disease Pipeline | Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,150 | 0,00 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 5,400 | +1,89 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | ~ Delivered Record Annual Revenue with Full-Year Net PEDMARK- Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 12,200 | +1,33 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 4,940 | -0,80 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen | |
| NANOBIOTIX | 26,650 | -1,30 % | Nanobiotix S.A.: NANOBIOTIX Statement Regarding Recent Media Speculation | PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches... ► Artikel lesen |
SYNTHAVERSE SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,014 (-1,64 %) liegt der Kurs bei 0,841 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.